Pfizer buys its way into migraine with $11.6B Biohaven Pharma acquisition
Pfizer is turning to M&A to get its next blockbuster, buying Biohaven six months after the two companies began a commercialization pact centered on the […]
Pfizer is turning to M&A to get its next blockbuster, buying Biohaven six months after the two companies began a commercialization pact centered on the […]
The European Commission approved Biohaven Pharmaceuticals migraine drug rimegepant. While the regulatory decision marks another milestone for Biohaven, it’s also a win for Pfizer, which […]
Date: December 27, 2021 Issue #: 1640 Summary: The FDA has approved Trudhesa (Impel Neuropharma), a new dihydroergotamine nasal spray product, for acute treatment of […]
Biohaven Pharmaceuticals has seen strong U.S. market uptake for its oral migraine drug, Nurtec. With regulatory decisions looming around the world, the company has landed […]
Date: October 5, 2020 Issue #: 1608 Summary: An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without […]
Copyright © 2024 | WordPress Theme by MH Themes